Tenaya Therapeutics Incorporated is a biotechnology company that develops heart diseases therapies in the U.S. It uses cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic Hypertrophic Cardiomyopathy, and TN-301, a small molecule inhibitor of Histone Deacetylase 6 (HDAC6i) for use in heart gFailure with preserved ejection fraction (HFpEF), as well as genetic Dilated Cardiomyopathy (gDCM). The company was incorporated in 2016 and is headquartered in San Francisco, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$133.96 | A | |
$21.57 | A | |
$5.87 | A |